These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11109616)

  • 21. Increased nuclear factor-kappaB activation in peripheral blood monocytes of patients with rheumatoid arthritis is mediated primarily by tumor necrosis factor-alpha.
    Dichamp I; Bourgeois A; Dirand C; Herbein G; Wendling D
    J Rheumatol; 2007 Oct; 34(10):1976-83. PubMed ID: 17896809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.
    Fröde TS; Tenconi P; Debiasi MR; Medeiros YS
    Mediators Inflamm; 2002 Dec; 11(6):345-9. PubMed ID: 12581498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease.
    Karadag F; Kirdar S; Karul AB; Ceylan E
    Eur J Intern Med; 2008 Mar; 19(2):104-8. PubMed ID: 18249305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction.
    Brown DA; Moore J; Johnen H; Smeets TJ; Bauskin AR; Kuffner T; Weedon H; Milliken ST; Tak PP; Smith MD; Breit SN
    Arthritis Rheum; 2007 Mar; 56(3):753-64. PubMed ID: 17328047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ; Voskuyl AE; Lems WF; de Groot E; Nurmohamed MT; Tak PP; Dijkmans BA; Aarden L
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B.
    Serwin AB; Wasowicz W; Chodynicka B
    Nutrition; 2006 Sep; 22(9):860-4. PubMed ID: 16829029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
    Wållberg-Jonsson S; Cvetkovic JT; Sundqvist KG; Lefvert AK; Rantapää-Dahlqvist S
    J Rheumatol; 2002 May; 29(5):875-82. PubMed ID: 12022343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus.
    Rosenau BJ; Schur PH
    J Rheumatol; 2009 Apr; 36(4):753-6. PubMed ID: 19273453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis.
    Syngle A; Vohra K; Kaur L; Sharma S
    Scand J Rheumatol; 2009; 38(1):15-22. PubMed ID: 18766955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
    Mathsson L; Lampa J; Mullazehi M; Rönnelid J
    Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Inflammatory status in patients with end-stage renal disease: role of monocyte activation].
    Liang M; Wang L; Hou FF; Liu J; Liu ZQ; Tian JW
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):781-4. PubMed ID: 12919896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis.
    Wang SY; Liu YY; Ye H; Guo JP; Li R; Liu X; Li ZG
    J Rheumatol; 2011 May; 38(5):821-7. PubMed ID: 21362762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
    Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
    Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
    J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis.
    Matsunawa M; Isozaki T; Odai T; Yajima N; Takeuchi HT; Negishi M; Ide H; Adachi M; Kasama T
    Arthritis Rheum; 2006 Nov; 54(11):3408-16. PubMed ID: 17075825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis.
    Galarraga B; Khan F; Kumar P; Pullar T; Belch JJ
    Rheumatology (Oxford); 2009 Nov; 48(11):1418-23. PubMed ID: 19734293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
    Svenungsson E; Gunnarsson I; Fei GZ; Lundberg IE; Klareskog L; Frostegård J
    Arthritis Rheum; 2003 Sep; 48(9):2533-40. PubMed ID: 13130473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis.
    Lopez-Olivo MA; Gonzalez-Lopez L; Garcia-Gonzalez A; Villa-Manzano AI; Cota-Sanchez AR; Salazar-Paramo M; Varon-Villalpando E; Cardona-Muñoz EG; Gamez-Nava JI
    Scand J Rheumatol; 2006; 35(2):112-6. PubMed ID: 16641044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.